4//SEC Filing
STAAB THOMAS R II 4
Accession 0001127602-19-019143
CIK 0000882796other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 4:21 PM ET
Size
10.4 KB
Accession
0001127602-19-019143
Insider Transaction Report
Form 4
STAAB THOMAS R II
Senior Vice President and CFO
Transactions
- Sale
Common Stock
2019-05-17$7.45/sh−2,500$18,625→ 125,176 total - Sale
Common Stock
2019-05-16$7.72/sh−7,250$55,970→ 127,676 total - Exercise/Conversion
Common Stock
2019-05-16$1.42/sh+4,750$6,745→ 134,926 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2019-05-16−4,750→ 61,000 totalExercise: $1.42From: 2014-01-01Exp: 2023-01-01→ Common Stock (4,750 underlying)
Footnotes (3)
- [F1]The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.55 to $8.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.41 to $7.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001230708
Filing Metadata
- Form type
- 4
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 4:21 PM ET
- Size
- 10.4 KB